Cargando…

Effectiveness of Concomitant Enteral Nutrition Therapy and Infliximab for Maintenance Treatment of Crohn’s Disease in Adults

BACKGROUND: One of the problems associated with infliximab (IFX) treatment for Crohn’s disease (CD) is loss of response during maintenance therapy. AIMS: The aim of this multicenter, retrospective, cohort study was to determine whether enteral nutrition (EN) added to the IFX therapy regimen is effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirai, Fumihito, Ishihara, Hiroshi, Yada, Shinichirou, Esaki, Motohiro, Ohwan, Tomohisa, Nozaki, Ryoichi, Ashizuka, Shinya, Inatsu, Haruhiko, Ohi, Hidehisa, Aoyagi, Kunihiko, Mizuta, Yohei, Matsumoto, Takayuki, Matsui, Toshiyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661072/ https://www.ncbi.nlm.nih.gov/pubmed/22926500 http://dx.doi.org/10.1007/s10620-012-2374-2

Ejemplares similares

Effect of a concomitant elemental diet with maintenance anti‐tumor necrosis factor‐α antibody therapy in patients with Crohn's disease: A multicenter, prospective cohort study
por: Hirai, Fumihito, et al.
Publicado: (2018)

Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab
por: Ashizuka, Shinya, et al.
Publicado: (2019)

Adrenomedullin for biologic‐resistant Crohn's disease: A randomized, double‐blind, placebo‐controlled phase 2a clinical trial
por: Kita, Toshihiro, et al.
Publicado: (2022)

Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial
por: Kita, Toshihiro, et al.
Publicado: (2020)

Adrenomedullin Therapy in Patients with Refractory Ulcerative Colitis: A Case Series
por: Ashizuka, Shinya, et al.
Publicado: (2015)

Adrenomedullin: A Novel Therapeutic for the Treatment of Inflammatory Bowel Disease
por: Ashizuka, Shinya, et al.
Publicado: (2021)

Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021)

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
por: Kobayashi, Taku, et al.
Publicado: (2015)

A Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene, Encoding a Prostaglandin Transporter
por: Umeno, Junji, et al.
Publicado: (2015)

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
por: Koga, Akihiro, et al.
Publicado: (2018)

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
por: Hisamatsu, Tadakazu, et al.
Publicado: (2018)

Capsule endoscopy findings for the diagnosis of Crohn’s disease: a nationwide case–control study
por: Esaki, Motohiro, et al.
Publicado: (2018)

Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease: A retrospective cohort study
por: Komaki, Yuga, et al.
Publicado: (2021)

Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021
por: Nakase, Hiroshi, et al.
Publicado: (2023)

Current status of endoscopic balloon dilation for Crohn's disease
por: Hirai, Fumihito
Publicado: (2017)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Single Rectal Neuroendocrine Tumor Associated with Multiple Endocrine Cell Micronests
por: Suzuki, Sho, et al.
Publicado: (2019)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

A new endoscopic scoring system corresponding to histological healing using linked color imaging in ulcerative colitis: the SOUL study
por: Saito, Daisuke, et al.
Publicado: (2023)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

Intermittent Purpura Development Associated with Leukocytoclastic Vasculitis Induced by Infliximab for Crohn's Disease
por: Kishimoto, Kenichi, et al.
Publicado: (2020)

Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy
por: Nakashima, Koji, et al.
Publicado: (2017)

Clinical features of chronic enteropathy associated with SLCO2A1 gene: a new entity clinically distinct from Crohn’s disease
por: Umeno, Junji, et al.
Publicado: (2018)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
por: Louis, Edouard, et al.
Publicado: (2023)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

Infliximab as an alternative therapy for refractory adult onset Kawasaki disease: A case report
por: Kawaguchi, Takeshi, et al.
Publicado: (2018)

Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn’s disease
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2018)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

Maintenance treatment with infliximab for the management of Crohn’s disease in adults
por: Caviglia, Renato, et al.
Publicado: (2009)

Infliximab-induced intertriginous psoriasis in patient with Crohn's disease
por: Mola, Federica, et al.
Publicado: (2011)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
por: Kim, You Lim, et al.
Publicado: (2014)

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
por: Timper, Katharina, et al.
Publicado: (2013)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
por: Aginbay, Aibar, et al.
Publicado: (2022)

Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan
por: Tajiri, Hitoshi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1cdfhvo6132fj60kdn06saivn0